Sign In
Buy EARS
$0.750
-0.0010 (-0.133%)
At Close: May 27, 2022
EARS Stock: Over 9% Increase Pre-Market Explanation
06:26am, Monday, 12'th Apr 2021
The stock price of Auris Medical Holding Ltd (NASDAQ: EARS) increased by over 9% pre-market. This is why it happened.
Why Auris Medical, CytoDyn and Prometheus Shares Are Moving Today
11:48am, Thursday, 08'th Apr 2021
Auris Medical Holding Ltd. (NASDAQ: EARS), CytoDyn Inc. (OTC: CYDY) and Prometheus Biosciences, Inc. (NASDAQ: RXDX) are among the biggest movers in the biopharma space Thursday.
EARS Stock Price Increased Over 4% Pre-Market: Why It Happened
08:45am, Wednesday, 31'st Mar 2021
The stock price of Auris Medical Holding Ltd. (NASDAQ: EARS) increased by over 4% pre-market.
Auris Medical Provides Business Update and Reports Second Half and Full Year 2020 Financial Results
08:30am, Wednesday, 31'st Mar 2021
Hamilton, Bermuda, March 31, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology
EARS Stock Price Increased 52.05%: Why It Happened
08:05am, Wednesday, 10'th Mar 2021
The stock price of Auris Medical Holding Ltd (NASDAQ: EARS) increased by 52.05% yesterday. This is why it happened.
Auris Medical Trading Higher On Increased Volume: Technicals To Watch
05:38pm, Friday, 05'th Mar 2021
Auris Medical Holding Ltd. (NASDAQ: EARS) shares traded on increased volume during Friday's trading session.
Auris Medical Announces Initiation of Clinical Investigation of AM-301 in Allergic Rhinitis
08:30am, Friday, 29'th Jan 2021
Hamilton, Bermuda, January 29, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotolo
Auris Medical Holding to Present at the 13th Annual LD Micro Main Event Conference
04:10pm, Monday, 07'th Dec 2020
Hamilton, Bermuda, December 7, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotolo
Auris Medical Holding Ltd. Prices $8,000,000 Common Shares Offering Priced At-the-Market
08:45am, Wednesday, 02'nd Dec 2020
Hamilton, Bermuda, December 2, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS) (“Auris” or the “Company”), a clinical-stage company dedicated to developing therapeutics that address importa
Auris Medical skyrockets 480% after announcing lab-test results that show its nasal spray could protect against Covid-19 (EARS)
03:47pm, Tuesday, 01'st Dec 2020
Auris Medical soared as high as 480% on Tuesday after it announced lab-test results that show its nasal spray could protect against the coronavirus. Shares of the Bermuda-based clinical stage company
EARS Stock: Why Auris Medical Shares Are Soaring 450%
01:30pm, Tuesday, 01'st Dec 2020
EARS stock typically flies under the radar, but today it is getting a boost thanks to trial data from a Covid-19 treatment. The post EARS Stock: Why Auris Medical Shares Are Soaring 450% appeared firs
Why Auris Medical's Stock Is Trading Higher By 445% Today
01:23pm, Tuesday, 01'st Dec 2020
Auris Medical (NASDAQ: EARS) shares are ripping higher on Tuesday after the company reported positive efficacy data for its AM-301 in protecting against Sars COVID-19 infections. Auris Medical Holding
Auris Medical Reports Positive In vitro Efficacy Data for AM-301 in Protecting Against Sars-CoV-2 Infection
09:00am, Tuesday, 01'st Dec 2020
Hamilton, Bermuda, December 1, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotolo
Auris Medical Launches Website for AM-301-focused Subsidiary, Altamira Medica
09:10am, Friday, 20'th Nov 2020
Hamilton, Bermuda, November 20, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotol
Auris Medical Announces Completion of Enrollment into First Part of TRAVERS Phase 2 Study with AM-125 in Vertigo
12:30pm, Wednesday, 29'th Jul 2020
* Dose escalation completed as last patient enrolled into Part A of TRAVERS study * Interim results to be announced in Q3 of 2020Hamilton, Bermuda, July 29, 2020 – Auris Medical Holding Ltd. (NASDA
